South China's Guangdong Province tops the country in terms of the number of pharmaceutical manufacturing permits, and medical apparatus and instrument enterprises.
Guangdong on Wednesday issued an action plan, aiming to boost annual revenue from its biopharmaceutical and health sector to over 1 trillion yuan by 2027.
British media commentator Jerry Grey, who lives in Guangdong, shares his insight on GBA's biopharma and medical improvements.
Related News